Addition of Financial Incentives to Mailed Outreach for Promoting Colorectal Cancer Screening: A Systematic Review and Meta-analysis.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
02 08 2021
Historique:
entrez: 25 8 2021
pubmed: 26 8 2021
medline: 11 1 2022
Statut: epublish

Résumé

Although screening decreases incidence of and mortality from colorectal cancer (CRC), screening rates are low. Health-promoting financial incentives may increase uptake of cancer screening. To evaluate the relative and absolute benefit associated with adding financial incentives to the uptake of CRC screening. PubMed, Cochrane Central Register of Controlled Trials, and Web of Science were searched from inception to July 31, 2020. Keywords and Medical Subject Headings terms were used to identify published studies on the topic. The search strategy identified 835 studies. Randomized clinical trials (RCTs) were selected that involved adults older than 50 years who were eligible for CRC screening, who received either various forms of financial incentives along with mailed outreach or no financial incentives but mailed outreach and reminders alone, and who reported screening completion by using recommended tests at different time points. Observational or nonrandomized studies and a few RCTs were excluded. The review was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). Data were abstracted and risk of bias was assessed by 2 independent reviewers. Random-effects meta-analysis was conducted, heterogeneity was examined through subgroup analysis and metaregression, and quality of evidence was appraised. The primary outcome was CRC screening completion within 12 months of receiving the intervention. A total of 8 RCTs that were conducted in the United States and reported between January 1, 2014, and December 31, 2020, were included. The trials involved 110 644 participants, of whom 53 444 (48.3%) were randomized to the intervention group (received financial incentives) and 57 200 (51.7%) were randomized to the control group (received no financial incentives). Participants were predominantly male, with 59 113 men (53.4%). Low-quality evidence (rated down for risk of bias and heterogeneity) suggested that adding financial incentives may be associated with a small benefit of increasing CRC screening vs no financial incentives (odds ratio [OR], 1.25; 95% CI, 1.05-1.49). With mailed outreach having a 30% estimated CRC screening completion rate, adding financial incentives may increase the rate to 33.5% (95% CI, 30.8%-36.2%). On metaregression, the magnitude of benefit decreased as the proportion of participants with low income and/or from racial/ethnic minority groups increased. No significant differences were observed by type of behavioral economic intervention (fixed amount: OR, 1.26 [95% CI, 1.05-1.52] vs lottery: OR, 1.06 [95% CI, 0.80-1.40]; P = .32), amount of incentive (≤$5: OR, 1.09 [95% CI, 1.01-1.18] vs >$5: OR, 1.25 [95% CI, 1.02-1.54]; P = .22), or screening modality (stool-based test: OR, 1.14 [95% CI, 0.92-1.41] vs colonoscopy: OR, 1.63 [95% CI, 1.01-2.64]; P = .18). Adding financial incentives appeared to be associated with a small benefit of increasing CRC screening uptake, with marginal benefits in underserved populations with adverse social determinants of health. Alternative approaches to enhancing CRC screening uptake are warranted.

Identifiants

pubmed: 34432010
pii: 2783480
doi: 10.1001/jamanetworkopen.2021.22581
pmc: PMC8387849
doi:

Types de publication

Journal Article Meta-Analysis Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2122581

Subventions

Organisme : NIDDK NIH HHS
ID : K23 DK117058
Pays : United States
Organisme : NIDDK NIH HHS
ID : R03 DK129631
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Cancer. 2018 Nov 1;124(21):4145-4153
pubmed: 30359473
JAMA Netw Open. 2019 Jul 3;2(7):e196570
pubmed: 31276178
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1796-1804.e2
pubmed: 31525514
Cancer Epidemiol Biomarkers Prev. 2018 Sep;27(9):1047-1056
pubmed: 29891726
Ann Intern Med. 2014 Nov 18;161(10 Suppl):S35-43
pubmed: 25402401
Gastroenterology. 2017 Nov;153(5):1227-1229.e2
pubmed: 28734830
Prev Med. 2019 Jan;118:113-121
pubmed: 30367972
JAMA Netw Open. 2019 Mar 1;2(3):e191156
pubmed: 30901053
Ann Intern Med. 2015 Jun 2;162(11):777-84
pubmed: 26030634
J Natl Cancer Inst. 2014 Apr;106(4):dju032
pubmed: 24681602
N Engl J Med. 2017 Jan 12;376(2):149-156
pubmed: 28076720
Ann N Y Acad Sci. 2019 Aug;1449(1):46-55
pubmed: 31111509
PLoS One. 2014 Mar 11;9(3):e90347
pubmed: 24618584
Clin Gastroenterol Hepatol. 2021 Aug;19(8):1635-1641.e1
pubmed: 32623005
N Engl J Med. 1993 Dec 30;329(27):1977-81
pubmed: 8247072
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
JAMA Intern Med. 2018 Dec 1;178(12):1645-1658
pubmed: 30326005
J Clin Epidemiol. 2011 Dec;64(12):1283-93
pubmed: 21839614
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Health Policy. 2019 Dec;123(12):1210-1220
pubmed: 31587819
Am J Gastroenterol. 2016 Nov;111(11):1630-1636
pubmed: 27481306
Stat Med. 2002 Feb 15;21(3):371-87
pubmed: 11813224
N Engl J Med. 2012 Feb 23;366(8):687-96
pubmed: 22356322
Gastroenterology. 2017 Jul;153(1):307-323
pubmed: 28600072
JAMA. 2016 Jun 21;315(23):2564-2575
pubmed: 27304597
Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1902-1908
pubmed: 31387970
Am J Gastroenterol. 2018 Dec;113(12):1739-1741
pubmed: 30413821
Prev Med Rep. 2020 May 08;19:101114
pubmed: 32477853

Auteurs

Antonio Facciorusso (A)

Gastroenterology Unit, Ospedali Riuniti di Foggia, Foggia, Italy.

Joshua Demb (J)

Moores Cancer Center, University of California at San Diego, La Jolla.

Babu P Mohan (BP)

Division of Gastroenterology and Hepatology, University of Utah School of Medicine, Salt Lake City.

Samir Gupta (S)

Moores Cancer Center, University of California at San Diego, La Jolla.
Section of Gastroenterology, Veterans Affairs San Diego Healthcare System, San Diego, California.
Division of Gastroenterology, University of California at San Diego, La Jolla.

Siddharth Singh (S)

Division of Gastroenterology, University of California at San Diego, La Jolla.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH